Introduction
Pancreatic cancer is one of the leading causes of malignancy-related death in the world. Due to the lack of effective means for screening and early diagnosis, most cases have already lost the chance of radical surgery and respond poorly to therapy when they are detected, thus the survival rate is extremely low (1, 2) . Accumulating evidence has indicated that both genetic and environmental factors are involved in pancreatic cancer carcinogenesis (3À5). In recent years, many efforts have been made to identify genetic susceptibility factors of pancreatic cancer, which might serve as specific biomarkers for risk assessment and early diagnosis. Although some exciting findings have been achieved (6À9), it still remains a great deal of unexplained heritability in pancreatic cancer.
Copy number variation (CNV) is a prevalent form of genetic variation defined as a copy number change of a DNA fragment ranging from kilobases to megabases. It affects $12% of the human genome and may have great contribution to phenotypic variations by altering gene dosage directly or perturbing long-range gene regulation by position effects (10À13). Previous studies have shown that some CNVs are associated with distinct complex human diseases including cancer (14À17), suggesting that CNVs are important dimensions for studying the inherited basis of complex human diseases.
In our previous study, we explored the whole-genome germ line CNVs in 25 patients with pancreatic cancer and 25 cancer-free controls using Affymetrix Genome-Wide Human single nucleotide polymorphism (SNP) Array 5.0 (Wu,C., Huang,L., Yu,D., Tan,W. and Lin,D, unpublished data) and discovered a common CNV on chromosome 6q13, which has previously been designated as CNVR2966.1 (18) . Loss of the 6q13 has been reported to be a high frequency event in several cancers including pancreatic cancer (19À21). In addition, chromosome aberrations in the region of 6q13À21 may be associated with locally aggressive behavior of cartilage cancer (22) . These findings suggest that the 6q13 plays an important role in cancer formation and development.
In this study, we investigated the association between CNVR2966.1 and pancreatic cancer susceptibility in a case-control cohort consisting of 1027 pancreatic cancer cases and 1031 controls and explored the potentially functional relevance of this CNV. Our data demonstrate that CNVR2966.1 is associated with pancreatic cancer risk and functions as a potential trans-acting regulator of the CDKN2B gene.
Materials and methods

Study subjects
Patients with pancreatic cancer (n 5 1027) and cancer-free controls (n 5 1.031) were all Han Chinese (Supplementary Table I is available at Carcinogenesis Online) and a portion of these participants (397 cases and 907 controls) were described previously (6, 8) . Patients were recruited from Beijing (n 5 589), Shanghai (n 5 293) and Wuhan (n 5 145). All patients with pancreatic ductal adenocarcinoma were enrolled and there were no sex and age restrictions. The diagnosis of pancreatic ductal adenocarcinoma was confirmed by cytologic diagnosis or histopathological examination of biopsy or resected tissue specimens. Controls were cancer-free individuals randomly selected from a community cancer-screening program for early detection of cancer based on a physical examination in Beijing. Controls had no individual history of cancer and were frequency matched to patients for sex and age. At recruitment, informed consent was obtained from each subject and each participant was then interviewed to collect detailed information on demographic characteristics, such as sex and age, and related risk factors, such as cigarette smoking and diabetes mellitus history. This study was approved by the Institutional Review Board.
Genotyping of CNVR2966.1
Quantitative polymerase chain reaction (qPCR) method was used for genotyping CNVR2966.1. The primers and probes (Life Technologies, Carlsbad, CA), shown in Supplementary Table II, available at Carcinogenesis Online, were designed on the basis of the results of Affymetrix Genome-Wide Human SNP Array 5.0 (Affymetrix, Santa Clara, CA) and b-globin, which has been proved to be two copies per diploid genome (23) , was selected as reference. qPCR was performed on ABI 7900HT real-time PCR system (Applied Biosystems, Foster City, CA). A genomic DNA sample with two copies per diploid genome in the CNVR2966.1 locus found by Affymetrix Genome-Wide Human SNP Array 5.0 was selected as standard sample. Five serial 1:2 dilutions (20-1.25 ng) of the standard sample were used to generate standard curves of CNVR2966.1 and b-globin. Standard curves were performed in triplicate on each 384-well PCR plate and duplicate wells were set up for each test sample. The amount of test DNA samples for each reaction was controlled in the range of 2-10 ng. Negative control wells for CNVR2966.1 and b-globin were also included on each plate. The qPCR data were analyzed by sodium dodecyl sulfate 2.3 (Applied Biosystems). Copy number of CNVR2966.1 was defined as the nearest integer of the ratio of the template quantity for CNVR2966.1 to the template quantity for b-globin multiplied by 2. When there was no amplification of CNVR2966.1 but Abbreviations: CNV, copy number variation; CI, confidence interval; OR, odds ratio; TGF, transforming growth factor; qPCR, quantitative polymerase chain reaction; SNP, single nucleotide polymorphism. b-globin, we defined it as zero copy. The samples defined as zero copy by qPCR were validated by conventional duplex PCR using b-actin as reference.
For quality control, the square of Pearson correlation coefficient (R 2 ) for a standard curve of .98% was accepted. Case and control samples were mixed and performed together in each plate. A 10% random sample of cases or controls was tested twice by different investigators. Another platform, Quantigene Plex 2.0 (Affymetrix), which is based on branched DNA signal amplification technology other than qPCR, was also used to analyze 10% random sample of cases or controls using both b-globin and ribonuclease P RNA component H1 (RPPH1) as reference genes and the accordance was 99.6%.
Cell lines and culture AsPC-1 and PANC-1, derived from pancreatic cancer, and HeLa, derived from cervical cancer, were obtained from American Tissue Culture Collection (Manassas, VA). KYSE-150, derived from esophageal cancer, was kindly provided by Dr Y.Shimada (Kyoto University, Kyoto, Japan). All cell lines were cultured in RPMI 1640 (Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (Biochrom AG, Berlin, Germany) under 37°C in humidified atmosphere containing 5% CO 2 .
Mapping CNVR2966.1 breakpoints HeLa cell line and 10 subjects with zero copy of CNVR2966.1 determined by both qPCR and conventional duplex PCR were selected to analyze exact breakpoints. A set of conventional PCR primers were designed toward the flanking region of the 5# putative breakpoint deduced from the allele intensity of the Affymetrix Genome-Wide Human SNP Array 5.0 SNP probes to determine the approximate range of CNVR2966.1 5# exact breakpoint position by walking across the critical region. Then the DNA Walking SpeedUp Premix Kit (Seegene, Seoul, Korea) and sequencing were used to identify the exact breakpoints of CNVR2966.1.
In silico analysis NCBI36/hg18 human reference sequence was used in this study. The sequence of CNVR2966.1 was downloaded from UCSC (http://genome.ucsc.edu/) (24, 25) . Ensembl Genome Brower (http://www.ensembl.org/index.html) and several tracks of the UCSC Genome Browser were used to analyze CNVR2966.1: Genes and Gene Prediction Tracks (RefSeq Genes, UCSC Genes, Ensemble Genes and RNA genes) for searching the known or predicted genes including non-coding RNA genes (26À33) and Regulation Tracks (EN-CODE Integrated Regulation Tracks, Open Chromatin, 7X Reg Potential) for exploring potential regulatory elements (34À37).
Luciferase reporter gene assay
For facilitating functional experiments, the pGL3-promoter vector (Promega, Madison, WI) was modified according to the Universal USER Cassette (New England Biolabs, Beverly, MA) protocol with some modifications. Briefly, we removed the XbaI site by site-specific mutation and inserted double strand oligonucleotides (sense 5#-GCTGAGG-GAAAGTCTAGAGGATCCTCTAGATGTCTCCTCAGC-3#, antisense 5#-GCTGAGGAGACATCTAGAGGATCCTCTAGACTTTCCCTCAGC-3#) in the SmaI clone site of the pGL3-promoter vector, generating pGL3-PU vector. The pGL3-PU vector was digested with XbaI and Nt.BbvC I (New England Biolabs) to generate linearized nicked vector for subsequent plasmid construction. Cloning primers were designed to amplify target sequence with extension oligonucleotides 5#-GGAGACAU-3# or 5#-GGGAAAGU-3# in their 5# end. PCR products were digested with USER enzyme (New England Biolabs) and cloned into the linearized nicked pGL3-PU vector prepared as described above. The plasmid containing $1.6 kb core potential regulator region of CNVR2966.1 (chromosome 6: 74 653 002À74 654 660) was designated as P-R, whereas the plasmids encompassing two DNA fragments of the upstream sequence of CDKN2B were designated as P-1 (chromosome 9: 22 004 767À22 007 408) and P-5 (chromosome 9: 22 002 663À22 005 029), respectively. The P-1 construct was digested by KpnI or KpnI and NruI, respectively, and then blunted by Klenow DNA Polymerase I (New England Biolabs) to generate construct P-2 or P-3. The P-5 construct was digested with BglII and EcoRI and then blunted by Klenow DNA Polymerase I to generate construct P-4. The resultant plasmids were restriction mapped and sequenced to confirm their authenticity.
Cell lines, AsPC-1, PANC-1, KYSE-150 and HeLa, were used for luciferase assays of P-R plasmid, whereas cell lines AsPC-1 and PANC-1 were used for luciferase assays of the plasmids encompassing the upstream sequence of CDKN2B. Cells were cultured in multi-well plates and grown to 60-70% confluence. The constructed reporter plasmid or the blank pGL3-promoter plasmid was cotransfected with pRL-SV40 (Promega) to the cells, respectively, using Lipofectamine reagent (Life Technologies). The pRL-SV40, containing Renilla reniformis luciferase, was used to standardize transfection efficiency. For each plasmid, at least three independent transfection experiments were done, and each was performed in triplicate.
Circular chromosome conformation capture
The procedure of circular chromosome conformation capture (4C) assay was performed as described previously with modifications (38, 39) . KYSE-150 cells (1 Â 10 7 ) were cross-linked in 2% formaldehyde for 10 min at room temperature and ice-cold glycine was added to quench the cross-linking reaction at final concentration of 0.125 M. After two washes with phosphate-buffered saline, cells were dissolved in cold lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 0.2% NP-40) containing freshly prepared protease inhibitors (Roche Diagnostics, Mannheim, Germany) and incubated for 30 min on ice. After centrifugation (400g) for 5 min at 4°C, the supernatant was removed and nuclei were collected. Nuclei were resuspended in DpnII buffer (New England Biolabs) with 0.3% sodium dodecyl sulfate and incubated at 37°C for 1 h with gently shaking, followed by the addition of 20% Triton X-100 at the final concentration of 2% and incubation for another 1 h at 37°C with shaking. Then, 1000 U of DpnII (New England Biolabs) were added to the sample and the mixture was incubated overnight at 37°C with shaking. After the addition of sodium dodecyl sulfate at the final concentration of 1.6%, the sample was incubated at 65°C for 25 min. Before incubation at 37°C for 1 h, the digestion mixture was diluted to $2 ng/ll of genomic DNA with 1Â T4 ligase buffer (New England Biolabs) and 1% Triton X-100. T4 DNA ligase (New England Biolabs) was added to the digested DNA sample followed by another incubation at 4°C for 1 week. The DNA sample was then treated with Proteinase K to reverse the DNA cross-links and purified by phenol extraction.
The DNA sample was amplified by PCR using the high-fidelity DNA polymerase Phusion (Finnzymes, Vantaa, Finland). A series of 30, 60 and 120 ng of 4C samples was tested to check the linearity of the 4C PCR and the reproduction of 4C PCR products' banding pattern. PCR products were separated on a 1.5% agarose gel and quantified by the optical intensity distribution curves. Several 4C PCR products were pooled for Solexa sequencing (Illumina, San Diego, CA). The resultant sequences were mapped against NCBI36/hg18. A genomic location that had a top peak of sequence read counts was considered to be the region interacted physically with CNVR2966.1 most frequently.
Real-time analysis of messenger RNAs Some candidate genes frequently interacted with CNVR2966.1 were chosen for transcriptional analysis (see Supplementary Table III, available at Carcinogenesis Online). The criteria for choosing candidate genes were: (i) The interaction with CNVR2966.1 had strong 4C signal, (ii) the 4C signal was located within a gene locus or 10 kb upstream of a gene and (iii) previous studies have demonstrated a role of the gene in cancer, especially in pancreatic cancer. Total RNA was isolated from biopsy or surgically removed normal adjacent pancreatic tissues (n 5 31) and then converted to complementary DNA using oligo (dT) primer and M-MLV Reverse Transcriptase (Promega). Messenger RNA levels were measured by quantitative reverse transcription-PCR in triplicate in an ABI 7900HT real-time PCR system (Applied Biosystems) with SYBR Premix Ex Taq (Takara, Shiga, Japan). The measurement of individual messenger RNA level was calculated relative to GAPDH using a comparative C T method (40) . All analyses were performed with the investigators being unaware of genotyping data.
Examination of physical interaction of CNVR2966.1 with CDKN2B upstream sequence The physical interaction between CNVR2966.1 and the upstream sequence of CDKN2B was validated independently by conventional PCR in KYSE-150 cells having both CNVR2966.1 and CDKN2B loci. The HeLa cell line carrying zero copy of CNVR2966.1 was served as negative control. Cell dispersion, formaldehyde cross-linking and DpnII digestion were executed as described previously. The digested samples were ligated with T4 DNA ligase for 4 h at 16°C. The DNA samples were purified by phenol extraction. Primers for CNVR2966.1 and the upstream sequence of CDKN2B were designed based on the 4C sequencing results. PCR products were analyzed on agarose gel and validated by DNA sequencing.
Statistical analysis
A two-sided v 2 test was used to examine the differences in demographic variables and distributions of CNVR2966.1 genotypes between cases and controls. The association of CNVR2966.1 genotype with pancreatic cancer risk was estimated by odds ratios (ORs) and their 95% confidence intervals (CIs) computed by unconditional logistic regression models and adjusted for sex, age, smoking status and diabetes mellitus history. These statistical analyses were implemented in Statistic Analysis System software (version 9.0; SAS Institute, Cary, NC). A t-test was used to examine the differences in luciferase reporter gene expression and the messenger RNA levels with different genotypes. P ,0.05 was used as the criterion of statistical significance.
CNV at 6q13 and pancreatic cancer Results
Association of CNVR2966.1 with pancreatic cancer risk
The selected characteristics of cases and controls are summarized in Supplementary Table I, available at Carcinogenesis Online. Briefly, there were no significant differences in the distribution of sex and age between cases and controls, suggesting that the frequency matching of cases and controls was adequate. However, individuals who smoked or had diabetes mellitus history were overrepresented in cases compared with controls, which are consistent with the well-known concept that smoking and diabetes mellitus are risk factors for the development of pancreatic cancer. Of the 1027 patients with pancreatic cancer, 55.4% had detailed tumor staging data at the time of diagnosis, with the most (57.3%) being in III and IV stages.
The genotype distribution of CNVR2966.1 was in agreement with that expected under Hardy-Weinberg equilibrium in controls. The frequencies of the three genotypes in cases were 37.5% (two copies), 51.4% (one copy) and 11.1% (zero copy), which differed significantly from those in controls [43.9% (two copies), 43.5% (one copy) and 12.6% (zero copy), P 5 0.001]. Logistic regression analysis revealed that an increased risk of pancreatic cancer was associated with the one copy genotype of CNVR2966.1 compared with the two copies genotype of CNVR2966.1 (adjusted OR 5 1.31, 95% CI 5 1.08-1.60, P 5 0.007). Although we did not find significant association between zero copy genotype with the risk (adjusted OR 5 0.99, 95% CI 5 0.73-1.34, P 5 0.923), which might be due to a limited statistical power because of relative low frequency of zero copy genotype, a significantly increased risk was seen when groups of zero and one copy genotypes were pooled for analysis (adjusted OR 5 1.24, 95% CI 5 1.03-1.50, P 5 0.023) ( Table I) .
Determination of exact breakpoints of CNVR2966. 1 We found that all 10 subjects and HeLa cell line used for mapping the exact breakpoints of CNVR2966.1 carried the same 10 379 bp nucleotides deletion within the uniform boundaries of chromosome 6: 74 648 791À74 659 169 (Figure 1 ). The nearest gene CD109 is $54 kb centromeric from CNVR2966.1. In the CNVR2966.1 region, we did not find any known or predicted coding genes or non-coding RNA genes. However, we discovered a core potential regulator region, which has relative enrichment of enhancer histone modification marker H3K4me1 in several cell lines compared with other regions (41) . In addition, the core potential regulator region is also a DNaseIhypersensitive region and has three confertim potential regulatory elements predicted by ESPERR (http://www.bx.psu.edu/projects/ esperr/) (42) (Figure 1) . 
Effect of CNVR2966.1 on reporter gene expression
To investigate the potential function of CNVR2966.1, we constructed a reporter plasmid encompassing the core potential regulator region (designated as P-R) and transiently transfected it into AsPC-1, PANC-1, KYSE-150 and HeLa cells. We found that the P-R plasmid drove a significantly higher luciferase expression than the pGL3-promoter plasmid (all P , 0.05), with the values (mean ± SD) being 1.65 ± 0.12 versus 1.00 ± 0.02 in AsPC-1, 1.47 ± 0.10 versus 1.00 ± 0.10 in PANC-1, 1.42 ± 0.12 versus 1.00 ± 0.05 in KYSE-150 and 1.46 ± 0.04 versus 1.00 ± 0.05 in HeLa (Figure 2A ).
Identification of CDKN2B as CNVR2966.1-targeting gene Because CNVR2966.1 is located in a region on 6q13 harboring no known or predicted gene (gene desert), it may function as a long-range regulator. To explore the potential genes targeted by CNVR2966.1, we conducted 4C assays for an unbiased genome-wide search for gene loci interacted with this CNV physically in the nuclear space. 4C PCR products appeared as smears on gel with some light bands. Highly reproducible band pattern between independent experiments and linear increase in PCR products with linear increase in amount of 4C sample input were shown in gel (Supplementary Figure 1A is available at Carcinogenesis Online). The similar shape of the three optical intensity distribution curves also indicated the reproducibility of independent experiments. The linearity of the 4C PCR reaction manifested itself in the form of the optical intensity change (Supplementary Figure 1B is available at Carcinogenesis Online).
The resultant sequences from Solexa sequencing of the 4C PCR product were mapped against NCBI36/hg18. In agreement with the idea that interaction frequencies are inversely proportional to the distance between the interacted DNA sequences, we found that there were strongest signals around CNVR2966.1 ( Figure 2B ) and a lot of gene loci interacted with CNVR2966.1. We then chose CDKN2B, CENPW, TGFA, WASF1, NMBR, NCOA3, IGF2R and SMAD3 as candidate genes for subsequent analysis of transcripts because of their strong 4C signals, proper interacting site and known roles in carcinogenesis. CD109 was also selected because it is the nearest gene from the CNV (Supplementary Table III is available at Carcinogenesis Online). The associations between the transcript levels of candidate genes in pancreatic tissues and CNVR2966.1 genotype were then analyzed for searching the specific functional interactions rather than random collisions.
We found that the CDKN2B transcript levels in pancreatic tissues were significantly associated with CNVR2966.1 genotypes ( Figure 3A) , with the value (mean ± SD) being significantly lower in one copy carriers than that in two copy carriers [0.51 ± 0.38 (n 5 18) versus 0.91 ± 0.51 (n 5 10), P 5 0.024]. Null copy carriers also had lower CDKN2B RNA levels (0.27 ± 0.17) than two copy carriers although the difference was marginally significant (P 5 0.062) probably due to limited number of null copy carriers (n 5 3) for analysis. These results are consistent with the Solexa sequencing results showing a cluster of strong signal in 9p21.3 ( Figure 2B ) where CNVR2966.1 interacted with $5 kb upstream of CDKN2B ( Figure 3B ). No significant associations between the transcript levels of other genes in pancreatic tissues and CNVR2966.1 genotype were found while the CD109 RNA levels were marginally significant higher (P 5 0.057) in individuals carrying two copies of CNVR2966.1 than that in zero or one copy carriers (Supplementary Table III is available at Carcinogenesis Online).
Validation of functional interaction between CNVR2966.1 and CDKN2B
In the independent validation of 4C signal by conventional PCR, the interaction between CNVR2966.1 and the upstream sequence of CDKN2B was readily visualized in KYSE-150 cells having both CNVR2966.1 and CDKN2B loci. In contrast, there was no same PCR product in HeLa cells without CNVR2966.1 locus. We cloned the specific PCR product from KYSE-150 cells for sequencing validation and the results clearly indicated that the PCR product was the ligation of CNVR2966.1 and the upstream sequence of CDKN2B in the DpnII restriction endonuclease site ( Figure 3C) .
To examine the effect of the upstream sequence of CDKN2B interacted with CNVR2966.1, a set of deletion constructs of CDKN2B upstream sequence was generated and transfected into pancreatic cell lines, AsPC-1 and PANC-1 ( Figure 4A ). Except for P-5, all constructs drove a significantly higher luciferase expression than the pGL3-promoter plasmid (all P , 0.05, Figure 4B) . Interestingly, the P-3 construct displayed a comparable or even higher activity compared with P-1 or P-2, implying an important upregulating effect of the region between À5454 and À6708. These results indicated that the physical interaction between CNVR2966.1 and the upstream functional sequence of CDKN2B may be associated with activation of CDKN2B transcription.
Discussion
In the present study, we demonstrated that a CNV located in a gene desert region on 6q13, CNVR2966.1, is significantly associated with the risk for developing pancreatic cancer. We mapped the exact breakpoints of CNVR2966.1 and found it a 10 379 bp nucleotides deletion/ insertion within the uniform boundaries of chromosome 6: 74 648 791À 74 659 169. 4C and other functional experiments showed that CNVR2966.1 might contain a transcriptional activation element and regulate the transcription of CDKN2B on 9p21.3 by interchromosomal long-range interaction. To the best of our knowledge, this is the first study investigating the effect of CNV on susceptibility to pancreatic CNV at 6q13 and pancreatic cancer cancer and exploring the long-range regulatory mechanism of CNV located in a gene desert region.
CNVs encompass more nucleotide content per genome than SNPs and there are 2908 RefSeq genes including some proven diseasecausing genes that overlap with the identified CNV regions (10) . A number of studies have revealed that many CNVs overlapping known genes predispose to increased disease susceptibility. A wellknown example is the low copy number of CCL3L1 that has been associated with increased susceptibility to AIDS (17) . In addition, CNV in a new gene on 1q21.1 has been associated with neuroblastoma (14) . On the other hand, a large proportion of known CNVs including some disease-causing CNVs occur in gene desert regions. For example, a germ line CNV on 2p24.3 gene desert was found to be associated with aggressive prostate cancer risk (16) . The exact mechanism for these CNVs in gene desert to contribute to phenotypic variations remains to be elucidated. Interestingly, a genome-wide study has shown that the effects of up to 50% CNVs accounted for gene expression quantitative trait may be explained by impact on regulatory elements or gene disruption rather than altering gene dosage (11) . Thus, we hypothesized that CNVR2966.1 associated with pancreatic cancer risk identified in our study might play its role by impact on some regulatory elements. In consistent with this hypothesis, we found that CNVR2966.1 might regulate CDKN2B expression by long-range position effect and different CDKN2B transcript abundance is associated with CNVR2966.1 genotype. CDKN2B encoding a cyclin-dependent kinase inhibitor has been considered as a critical tumor suppressor. It prevents the activation of cyclin-D-dependent kinases and regulates cell growth and the cell cycle G 1 progression (43) . CDKN2B has been found to be frequently co-deleted with adjacent tumor suppressor gene CDKN2A in a variety of tumors. In pancreatic cancer, CDKN2B deletion has been reported in a considerablely high proportion (21, 44) .
Accumulative evidence has shown that the spatial organization of chromosomes is a key contributor to transcriptional regulation of genes in cis or trans. For example, interchromosomal interactions between a trans-acting enhancer element and multiple olfactory receptor promoters are associated with olfactory receptor choice (45) . Similarly, it has been demonstrated that active and inactive genes are engaged in many long-range intrachromosomal or interchromosomal interactions (46) . Moreover, some disease-associated SNPs in gene desert regions identified by genome-wide association studies are located in regulatory elements and play their roles in disease development by long-range regulation of neighboring or distant genes (47À50). We conducted 4C assays to explore the potential target genes regulated by CNVR2966.1 and found a long-range regulatory effect on CDKN2B. These findings provided the first example for the long-range regulatory mechanism of CNV located in gene desert.
Determination of the exact breakpoints of CNV is crucial for understanding the potential mutational mechanism and assessing its functional impact. The exact breakpoints of CNVR2966.1 have not been characterized precisely so far. In this study, we mapped its breakpoints to base-pair resolution in 10 subjects and HeLa cell line. All the samples for breakpoint analysis are within the uniform boundaries. Based on the exact boundaries, in silico analysis found a core potential regulator region located in CNVR2966.1, which is DNaseI hypersensitive and relatively rich in H3K4me1 and had three confertim potential regulatory elements predicted by ESPERR (42) . DNaseI hypersensitivity signifies chromatin accessibility which is a universal feature of active regulatory sequences, and the enrichment of H3K4me1 is the marker of enhancer elements (41, 51) . Reporter gene assays indicated that the construct encompassing the core potential regulator region of CNVR2966.1 had active regulatory activity in several cell lines originated from the pancreas, esophagus and cervix, implying CNVR2966.1 may function as an activation regulator in a universal manner.
Our transcriptional analyses found that the levels of CD109 and CENPW transcripts were also marginally significantly associated with CNVR2966.1 genotypes in pancreatic tissues. These marginally significant associations may be due to limited samples for transcriptional analysis. It is worthy to note that CD109, a component of the transforming growth factor (TGF)-beta pathway, functions as a suppressor of TGF-beta signaling (52, 53) while TGF-beta induces CDKN2B expression, which is involved in the TGF-beta-mediated cell cycle arrest (54) . The null association between zero copy of CNVR2966.1 and pancreatic cancer risk might reflect the small sample size in this subgroup, although the potential function of the CNV locus as a regulator of TGF-beta signaling needs further investigation.
In conclusion, our study found that CNVR2966.1 on 6q13 is associated with susceptibility to pancreatic cancer, which might be mediated by long-range regulation of CDKN2B or other tumor-related genes. Based on the large case-control analysis and functional assays, CNVR2966.1 is thought to be a believable genetic susceptibility factor of pancreatic cancer and it might be of importance for better understanding, risk assessment and early detection of the cancer. The major limitation of this study is lacking independent validation. Further studies are needed to validate our findings. 
